Carlos Andres Pinzón Arteaga

Carlos Andres Pinzón Arteaga

Auto-generated profile, based on publicly available information

Carlos Andres Pinzón Arteaga

Department of Molecular Biology, University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Cell Stem Cell
Verified
Journal Article
Closed access
LYLeqian Yu
Leqian Yu
YWYulei Wei
Yulei Wei
HSHai-Xi Sun
Hai-Xi Sun
AMAhmed K Mahdi
Ahmed K Mahdi
CACarlos A. Pinzon Arteaga
Carlos A. Pinzon Arteaga
JWJun Wu
Jun Wu

28 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
CZCanbin Zheng
Canbin Zheng
YHYingying Hu
Yingying Hu
MSMasahiro Sakurai
Masahiro Sakurai
CPCarlos A. Pinzon-Arteaga
Carlos A. Pinzon-Arteaga
JLJie Li
Jie Li
JWJun Wu
Jun Wu

16 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DWDiarra K. Williams
Diarra K. Williams
CPCarlos Pinzón
Carlos Pinzón
SHShannon Huggins
Shannon Huggins
JPJane H. Pryor
Jane H. Pryor
AFAlyssa Falck
Alyssa Falck
DGDana Gaddy
Dana Gaddy
The availability of tools to accurately replicate the clinical phenotype of rare human diseases is a key step toward improved understanding of disease progression and the development of more effective therapeutics. We successfully generated the first large animal model of a rare human bone disease, hypophosphatasia (HPP) using CRISPR/Cas9 to introduce a single point mutation in the tissue nonspecific alkaline phosphatase (TNSALP) gene (ALPL) (1077 C > G) in sheep. HPP is a rare inherited disorder of mineral metabolism that affects bone and tooth development, and is associated with muscle weakness. Compared to wild-type (WT) controls, HPP sheep have reduced serum alkaline phosphatase activity, decreased tail vertebral bone size, and metaphyseal flaring, consistent with the mineralization deficits observed in human HPP patients. Computed tomography revealed short roots and thin dentin in incisors, and reduced mandibular bone in HPP vs. WT sheep, accurately replicating odonto-HPP. Skeletal muscle biopsies revealed aberrant fiber size and disorganized mitochondrial cristae structure in HPP vs. WT sheep. These genetically engineered sheep accurately phenocopy human HPP and provide a novel large animal platform for the longitudinal study of HPP progression, as well as other rare human bone diseases.

2 December 2019 in Reproduction, Fertility and Development
Verified
Journal Article
Closed access
PDF file
MNMicaela Navarro
Micaela Navarro
DSDelia A. Soto
Delia A. Soto
CPCarlos A. Pinzon
Carlos A. Pinzon
JWJun Wu
Jun Wu
PRPablo Juan Ross
Pablo Juan Ross
Pluripotent stem cells (PSCs) have demonstrated great utility in improving our understanding of mammalian development and continue to revolutionise regenerative medicine. Thanks to the improved understanding of pluripotency in mice and humans, it has recently become feasible to generate stable livestock PSCs. Although it is unlikely that livestock PSCs will be used for similar applications as their murine and human counterparts, new exciting applications that could greatly advance animal agriculture are being developed, including the use of PSCs for complex genome editing, cellular agriculture, gamete generation and in vitro breeding schemes.

4 May 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CPCarlos Pinzon-Arteaga
Carlos Pinzon-Arteaga
MSMatthew D. Snyder
Matthew D. Snyder
CLCicera R. Lazzarotto
Cicera R. Lazzarotto
NMNicolas F. Moreno
Nicolas F. Moreno
RJRytis Juras
Rytis Juras
CLCharles R. Long
Charles R. Long
Phenotypic selection during animal domestication has resulted in unwanted incorporation of deleterious mutations. In horses, the autosomal recessive condition known as Glycogen Branching Enzyme Deficiency (GBED) is the result of one of these deleterious mutations (102C > A), in the first exon of the GBE1 gene (GBE1102C>A). With recent advances in genome editing, this type of genetic mutation can be precisely repaired. In this study, we used the RNA-guided nuclease CRISPR-Cas9 (clustered regularly-interspaced short palindromic repeats/CRISPR-associated protein 9) to correct the GBE1102C>A mutation in a primary fibroblast cell line derived from a high genetic merit heterozygous stallion. To correct this mutation by homologous recombination (HR), we designed a series of single guide RNAs (sgRNAs) flanking the mutation and provided different single-stranded donor DNA templates. The distance between the Cas9-mediated double-stranded break (DSB) to the mutation site, rather than DSB efficiency, was the primary determinant for successful HR. This framework can be used for targeting other harmful diseases in animal populations.

25 July 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
AAAlejandro De Los Angeles
Alejandro De Los Angeles
ARAlan Regenberg
Alan Regenberg
VMVictoria Mascetti
Victoria Mascetti
NBNissim Benvenisty
Nissim Benvenisty
GCGeorge Church
George Church
EZElias T. Zambidis
Elias T. Zambidis